Leucovorin: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Leucovorin. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Leukopenia | 93% |
| Stomatitis | 84% |
| Nausea | 80% |
| Diarrhea | 67% |
| Vomiting | 46% |
| Alopecia | 43% |
| Dermatitis | 25% |
| Anorexia | 22% |
| Thrombocytopenia | 18% |
| Hospitalization for toxicity | 15% |
| Lethargy/malaise/fatigue | 13% |
| Infection | 8% |
| Constipation | 4% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Leucovorin Calcium, USP rescue is indicated after high dose methotrexate therapy in osteosarcoma. Leucovorin Calcium, USP is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium, USP is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium, USP is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.